Modality
Small Molecule
MOA
TROP-2 ADC
Target
CD47
Pathway
Tau
GAIPF
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Feb 2029
ApprovedCurrent
NCT08853671
843 pts·GA
2025-10→2029-02·Not yet recruiting
NCT04325128
2,005 pts·IPF
2017-10→2027-03·Recruiting
NCT05168370
318 pts·IPF
2019-08→2026-02·Active
3,166 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2025-07-069mo agoAdCom· IPF
2026-02-122mo agoPh3 Readout· IPF
2027-03-0611mo awayPh3 Readout· IPF
2029-02-222.9y awayPh3 Readout· GA
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Recruit…
Approved
Active
Approved
Not yet…
Catalysts
AdCom
2025-07-06 · 9mo ago
IPF
Ph3 Readout
2026-02-12 · 2mo ago
IPF
Ph3 Readout
2027-03-06 · 11mo away
IPF
Ph3 Readout
2029-02-22 · 2.9y away
GA
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08853671 | Approved | GA | Not yet recr... | 843 | FEV1 |
| NCT04325128 | Approved | IPF | Recruiting | 2005 | OS |
| NCT05168370 | Approved | IPF | Active | 318 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |